Search results

Selected filters:

Life Sciences

Article type





121 results found for your search

Sort options
18 September 2017

The biggest problem with Allergan’s St Regis Mohawk deal is that the tribe may not own the patents

The transfer of six patents underpinning Allergan’s dry-eye treatment Restasis to the Saint Regis Mohawk native American Indian tribe has electrified the US patent community. The move, designed to make use of the tribe’s sovereign immunity in order…

04 September 2017

After four years in the role, Brian Hinman set to stand down as Philips chief IP officer

Brian Hinman, chief IP officer at Philips, will be leaving the company in the middle of this month, IAM can reveal. The departure is entirely amicable and has been driven by Hinman’s desire to be closer to and spend more time with his family. Since…

23 June 2017

Even if IPRs are deemed unconstitutional, not much will change - except for pharma sector, which will hate it

Since the US Supreme Court granted cert in Oil States Energy Services, a case which challenges the constitutionality of the IPR process, the patent community has been debating whether this might mark the end of post-issuance reviews. If that were to…

21 February 2017

PTAB issues key decision over revolutionary CRISPR technology, but this tale is not over yet

The gene-editing tool CRISPR is in the process of transforming the life sciences industry. Perhaps not surprisingly with such a revolutionary technology still in its relative infancy, a dispute over patents between universities and research…

02 December 2016

Latest issue of IAM reveals exclusive new data on the state of play in the US brokered patent market

Issue 81 of IAM has been published and is available online for subscribers. Hard copies are in the post and should be with you shortly. Everyone operating in the US patent market knows just how tough it is and brokers probably realise it more…

21 September 2016

IAM's first event for senior executives in the pharma and biotech sectors takes place in Munich this November

Senior corporate IP experts, litigation specialists and patent counsel will convene for Pharma and Biotech IP Summit in Munich on 3rd November 2016 to explore, compare and create strategies that designed to maximise the value of their intellectual…

18 December 2015

Patent reform stalls, Bass takes on pharma, litigation spikes plus plenty more – the US IP market in 2015

As we near the end of the year it’s list time and so here’s our run through of the most significant patent stories from the US. As with last year, we’ve ranked them in order of importance. Feel free to tell us where we got it wrong. Kyle Bass and…

13 December 2015

Sadly, Michelle Lee is wrong to believe the US IP system is gold standard and that it works for the little guy

A couple of weeks ago the IAM blog featured a two-part interview our North America correspondent Richard Lloyd did with USPTO Director Michelle Lee (Part One here and Part Two here). We were pleased to get it as Lee does not seem to have done too…

30 November 2015

USPTO Director Lee – “It’s not sound policy to allow potentially invalid patent claims to stand unchallenged”

Since she was appointed Deputy Director of the USPTO (and the acting head) and then confirmed as the Director in March this year, Michelle Lee has been in charge during a period of profound change in the US patent system. Patent reform has remained…

19 November 2015

From Congress to Wall Street new IAM event lifts the lid on how law and policy is shaping the patent market

IAM’s inaugural Patent Law and Policy event took place in Washington DC on Tuesday with five outstanding panels of speakers discussing the latest trends in law and policy, and how those two forces affect the monetisation landscape. Given the…

28 September 2015

Novartis is the latest Big Pharma player to extend olive branch in Third World patent rights row

While the global quarrel over the pricing of patented drugs continues unabated, Swiss pharmaceutical giant Novartis has announced that it will offer a number of its medicines at significant discount to developing countries. According to a press…

11 September 2015

Chances of patent reform this year look slim as Congress returns from summer break

Mark Cuban, entrepreneur, NBA team owner and star of the TV show Shark Tank (the US equivalent of the BBC’s Dragons’ Den) was on Capitol Hill this week in part to help bring a little stardust to the push for patent reform. Cuban is the backer of the…

31 July 2015

The companies that abandon most US and EPO patents – and shoulder much responsibility for raising quality

In the latest issue of IAM magazine – available for subscribers to view online from today – Matthew Beers and Maria Lazarova of Ocean Tomo take a deep-dive look at patent abandonments data from both the USPTO and EPO. The full article contains a…

17 July 2015

The Kyle Bass pharma patent IPR strategy looks to be a lot more sophisticated and long-term than many think

Last week we published an interview with Kyle Bass, the hedge fund investor who together with Erich Spangenberg, has petitioned to challenge a series of pharmaceutical patents through the inter partes review (IPR) process at the Patent Trial and…

16 July 2015

The Innovation Act is pulled, but uncertainty lingers and that’s bad for business

The Innovation Act was dramatically pulled from consideration last night just days before a vote on it was expected in the House of Representatives. It is now unlikely that the proposed legislation will be considered again until after the summer…